IOL Chemicals (IOLCP)

FairStock Score: 54/100 — MIXED

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Low debt: Debt/Equity of 0.09 provides financial stability.
• Promoter holding of 52.62% aligns management with minority shareholders.
• Profit growth of 40.88% and a PEG of 0.66 suggest improving earnings momentum.
• Piotroski F-Score of 7/9 indicates decent fundamental health.
• Book value of ₹56.25 provides some asset backing.

Concerns

• Low ROE of 7.00% and ROCE of 8.86% suggest weak competitive advantage and capital efficiency.
• Latest quarter net margin is thin: ₹21 Cr net profit on ₹580 Cr sales is only ~3.6%.
• P/E of 17.22 and P/B of 1.65 leave little margin of safety for a business with modest returns.
• Stock is down sharply from ₹179.65 high, which may signal deteriorating expectations rather than opportunity.

AI Analysis

At first glance, IOL Chemicals offers what looks like a recovering pharmaceutical story. Sales grew 10.91%, profits jumped 40.88%, and the PEG ratio of 0.66 tempts a value hunter. But I must resist the lure of a single ratio. The business earns only 7.00% on equity and 8.86% on capital employed. That is not the kind of return a wonderful franchise produces. In my world, a company's moat shows up in consistently high returns on capital. These numbers tell me IOL operates in a competitive, likely commoditized space where pricing power is limited. The latest quarter reinforces this: ₹580 Cr sales produced only ₹21 Cr net profit, a margin of about 3.6%. That is thin. Financially, the company is conservative: debt/equity is just 0.09, and the Piotroski F-Score of 7/9 suggests the balance sheet is improving. Promoters own 52.62%, so interests are aligned. Dividend yield is 1.37%, modest. However, at ₹92.61, I am paying 17.22 times earnings and 1.65 times book value for a business earning modest returns. That is not a margin of safety. The share sits far below its 52-week high of ₹179.65, but a falling stock price alone is not a reason to buy. I need the underlying earnings power to justify the price. The 40.88% profit growth lifts hope, but with ROE at 7%, the base was low. I would classify this as a turnaround candidate, not a stalwart. I will wait until I see ROE move sustainably higher and margins widen before calling it a great business. For now, it is a perhaps, not a conviction buy.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer